From b984a3f70e158e220c42dea68f850d9bea399bbe Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 30 Mar 2026 05:16:41 +0000 Subject: [PATCH] extract: 2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025 Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70> --- ...-loss-with-inflammation-as-primary-mediator.md | 12 ++++++++++++ ...lect-adiposity-independent-cv-outcomes-2025.md | 15 ++++++++++++++- 2 files changed, 26 insertions(+), 1 deletion(-) diff --git a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md index 45989f77b..0862e4fed 100644 --- a/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md +++ b/domains/health/semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md @@ -30,6 +30,18 @@ This has major implications: (1) the drug should benefit patients across the BMI ESC 2024 mediation analysis quantifies specific mediator contributions: hsCRP (inflammation) accounts for 42.1% of CV benefit, body weight only 19.5%, waist circumference 64.0%. Joint mediation of ALL measured factors (weight, inflammation, HbA1c, waist) explains only 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% unexplained. This confirms the weight-independence finding from the Lancet 2025 prespecified analysis and adds the specific breakdown showing inflammation mediates MORE than weight loss. +### Additional Evidence (confirm) +*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30* + +SELECT trial prespecified analysis (N=17,604) published in The Lancet November 2025 confirms ~67% of MACE reduction is independent of weight/adiposity changes. Treatment effect was consistent across ALL baseline BMI and waist circumference categories with no evidence of heterogeneity. Time-varying weight loss analysis showed 'no evidence that the treatment effect of semaglutide was mediated by time-varying weight loss.' Only ~33% of benefit explained by early waist circumference reductions. This is stronger evidence than the ESC 2024 abstract because it's a prespecified (not exploratory) analysis from the definitive SELECT publication. + +### Additional Evidence (confirm) +*Source: [[2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025]] | Added: 2026-03-30* + +ESC 2024 mediation analysis (Colhoun/Lincoff) found hsCRP (inflammation marker) mediated 42.1% of CV benefit while body weight mediated only 19.5%. Joint mediation of all measured metabolic factors was 31.4% (95% CI: -30.1% to 143.6%), leaving ~68.6% of benefit unexplained by adiposity or standard metabolic parameters. The convergence between this analysis (68.6% unexplained) and the Lancet prespecified analysis (67% weight-independent) from independent methodologies strengthens the anti-inflammatory mechanism hypothesis. + + + Relevant Notes: - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] diff --git a/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md b/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md index f29be32cc..e6e2859ca 100644 --- a/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md +++ b/inbox/queue/2026-03-30-lancet-select-adiposity-independent-cv-outcomes-2025.md @@ -7,9 +7,13 @@ date: 2025-11-01 domain: health secondary_domains: [] format: journal-article -status: unprocessed +status: enrichment priority: high tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mechanism, adiposity, MACE] +processed_by: vida +processed_date: 2026-03-30 +enrichments_applied: ["semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md", "semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -56,3 +60,12 @@ tags: [GLP-1, semaglutide, SELECT-trial, cardiovascular, weight-independent, mec PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: Closes active thread on GLP-1 CV mechanism; establishes weight-independence as the primary clinical finding; connects GLP-1 benefit to SDOH-generated inflammatory pathways EXTRACTION HINT: Focus on the 67-69% weight-independence figure and the hsCRP mediation (42.1%) — together these establish the anti-inflammatory mechanism. Extract as mechanism claim, not just efficacy claim. Consider whether this should be a divergence with the existing GLP-1 claim that frames the drug primarily through metabolic/weight-loss lens. + + +## Key Facts +- SELECT trial enrolled 17,604 adults ≥45 years with BMI ≥27 and pre-existing CVD but no diabetes at baseline +- Semaglutide 2.4mg weekly reduced MACE (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% overall +- Approximately 33% of MACE reduction was explained by early reductions in waist circumference +- hsCRP mediation analysis showed 42.1% of benefit attributable to inflammation pathways +- Body weight mediated 19.5% of cardiovascular benefit in ESC 2024 analysis +- The Lancet prespecified analysis was published November 2025, led by John Deanfield (UCL)